The phase two trial involves the use of Bionomics' BNC105 in combination with Bristol Myers Squibb’s PBS-listed immunotherapy OPDIVO (nivolumab) in patients with metastatic colorectal cancer. …
Bionomics-BMS combination completes trial treatment phase
January 22, 2021 Australian BiotechBioPharmaLatest News
Latest Video
New Stories
-
Azura Ophthalmics announces positive results in phase two program
March 9, 2021 - - Australian Biotech -
BMS' Dr Greg Cook on enhancing regulatory and reimbursement processes
March 9, 2021 - - Latest News -
Daily updates on COVID-19 vaccine - 9 March 2021
March 9, 2021 - - COVID-19 -
PAIG companies mark International Women's Day 2021
March 9, 2021 - - Latest News -
Time for intervention on this 'unlawful exercise of power'
March 9, 2021 - - Latest News -
The three women leading emerging Australian biotech
March 8, 2021 - - Australian Biotech -
Bupa's Emily Amos on the need for 'bold' reform
March 8, 2021 - - Other Health